Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) said its Italian unit submitted a request to the European Medicines Agency for CVMP scientific advice on pursuing EU approval of Canalevia (crofelemer) for general diarrhea in dogs based on a 2017 study of 200 dogs. The CVMP review is requested for its March 2026 meeting; EMA will have 60 days (extendable to 90) to respond. If EMA agrees the updated analysis supports approval, Jaguar would file a Marketing Authorization Application to sell Canalevia across the 27 EU member states. Jaguar also noted FDA conditional approval for chemotherapy-induced diarrhea in dogs and cited EU/US dog population and case estimates.
Jaguar Health (NASDAQ:JAGX) announced an Australian patent issued to Napo for methods treating short bowel syndrome (SBS), bile acid diarrhea, and post-resection diarrhea using an inhibitor of chloride-ion transport such as crofelemer (Nov 24, 2025).
Jaguar cited emerging proof-of-concept clinical data: two pediatric SBS-IF patients showed 12.5–15.6% reduction in parenteral support (PS) at 12 weeks; one MVID patient showed up to 27% reduction at 12 weeks and up to 37% on extension. Ongoing randomized trials and expanded access programs are active in US, EU, Middle East.
Jaguar Health (NASDAQ:JAGX) said Napo Pharmaceuticals submitted an amended protocol to the FDA on November 20, 2025 to support a possible expedited approval pathway for crofelemer to treat intestinal failure in pediatric patients with microvillus inclusion disease (MVID).
Company cites investigator-initiated trial data showing parenteral support (PS) reductions of 12–37% in pediatric intestinal failure patients and up to 27%–37% PS reduction in the initial MVID patient. Jaguar also discussed potential review with the EMA and is supplying crofelemer for two U.S. expanded access programs.
Jaguar Health (NASDAQ: JAGX) reported Q3 2025 net revenue of ~$3.1M, up ~4% versus Q2 2025, with Mytesi prescription volume up ~0.9% sequentially but down ~3.6% year-over-year. The company recorded a net loss attributable to common stockholders of $9.5M and non-GAAP recurring EBITDA of -$8.9M. License revenue of $42,858 was recognized and deferred contract revenue totaled ~ $595k as of September 30, 2025.
Clinical update: investigator-initiated proof-of-concept data suggest crofelemer may extend survival and reduce parenteral support volume by up to 37% in infants with MVID, though associated toxicity was reported. Jaguar met with the FDA on October 2, 2025 to discuss an expedited approval pathway for a placebo-controlled crofelemer trial.
Jaguar Health (NASDAQ:JAGX) announced it will file its Form 10-Q for the quarter ended September 30, 2025 on November 14, 2025 and will host an investor webcast to review Q3 2025 financials and corporate updates.
The webcast is scheduled for Monday, November 17, 2025 at 8:30 AM Eastern. Registration and participant access are available via the company’s registration link.
Jaguar Health (NASDAQ:JAGX) recap of a November 8, 2025 NASPGHAN presentation reported initial proof-of-concept results for crofelemer in pediatric intestinal failure (including MVID and SBS-IF).
The independent IIT in the UAE showed reductions in total parenteral support (PS) ranging from 12% to 37%: two SBS-IF patients had PS reductions of 12.5–15.6% over 12 weeks; one MVID patient showed up to 27% reduction in 12 weeks and up to 37% during an extension after reinitiation. Findings included reduced loose watery stools and support continued evaluation and placebo-controlled trials across U.S., EU and Middle East sites.
Jaguar Health (NASDAQ:JAGX) reminded investors that partial results from an investigator-initiated proof-of-concept trial of crofelemer in pediatric intestinal failure will be presented on November 8, 2025 at NASPGHAN.
Initial open-label UAE data show reductions in total parenteral support (PS) of 12%–37% in pediatric patients including microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). The company is supporting a placebo-controlled pediatric MVID trial across the U.S., EU and Middle East, supplying crofelemer for two FDA-authorized expanded access programs in the U.S., and supporting an IIT in U.S. adult SBS-IF patients.
Jaguar Health (NASDAQ:JAGX) announced on October 24, 2025 that, effective October 20, 2025, it granted inducement restricted stock units (RSUs) under Nasdaq Listing Rule 5635(c)(4).
The company awarded 600 RSUs to New Employee 1, 600 RSUs to New Employee 2, and 300 RSUs to New Employee 3, for a total of 1,500 RSUs. Each grant vests over one year from the employee's hire date and is conditioned on continued service through the applicable vesting dates. The grants were approved by Jaguar's Compensation Committee as material inducements to employment.
Jaguar Health (NASDAQ:JAGX) reported that its family company Napo met with the FDA on October 2, 2025 to seek advice on advancing a crofelemer powder oral solution development program for microvillus inclusion disease (MVID), an ultrarare pediatric disorder. The company said the FDA discussion identified potential opportunities to amend the ongoing study so a small, adequately controlled trial could support approval.
An investigator-initiated UAE trial patient showed a 37% weekly reduction in total parenteral support and a 30% reduction in total parenteral nutrition after reinitiation of crofelemer. Orphan designations exist from FDA and EMA; expanded access programs in the U.S. are authorized. An abstract was accepted for NASPGHAN Nov 5-8, 2025.
Jaguar Health (NASDAQ:JAGX) announced FDA authorization for expanded access programs using their novel crofelemer powder for oral solution to treat two pediatric intestinal failure patients with microvillus inclusion disease (MVID). The programs operate under separate Single-Patient Investigational New Drug applications in the US.
Initial proof-of-concept results from ongoing investigator-initiated trials showed that crofelemer reduced required total parenteral nutrition (TPN) by up to 27% in MVID patients and up to 12.5% in SBS-IF patients. The company expects additional trial results in 2025 and data from placebo-controlled studies in 2026.
Jaguar aims to pursue expedited regulatory pathways and potential early access programs in Europe, targeting a market of approximately 200 MVID patients worldwide and 10,000-20,000 SBS patients in both the US and Europe.